✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Valiant Laboratories Ltd.

VALIANTLAB

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹477 Cr.
P/E
0.00

Valiant Laboratories Ltd.

  • Valiant Laboratories
  • Brooks Laboratories
  • Medicamen Biotech

FAQs on Valiant Laboratories Ltd. Shareprice

Valiant Laboratories has given lower returns compared to its competitors.
Valiant Laboratories has grown at ~-26.17% over the last 1yrs while peers have grown at a median rate of -1.26%

Valiant Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Valiant Laboratories is 0.0, while 3 year average PE is 9.66.
Also latest EV/EBITDA of Valiant Laboratories is 4717 while 3yr average is 317.

View FAQ's On Business

Growth Table

  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Balance Sheet

  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Cash Flow

  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Quarterly Results

  • Valiant Laboratories Ltd.
  • Brooks Laboratories
  • Medicamen Biotech

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Valiant Laboratories Ltd. Financials

Balance sheet of Valiant Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Valiant Laboratories is increasing.
Latest net debt of Valiant Laboratories is -₹30.69 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹136.32 Crs.

No, profit is decreasing.
The profit of Valiant Laboratories is -₹2.2 Crs for Mar 2025, ₹0.32 Crs for Mar 2024 and ₹29 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Valiant Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech